Type 2 (which accounts for 10 to 30 percent of cases) is characterized by qualitative abnormalities of von Willebrand factor and is further divided into subtypes 2A, 2B, 2M, and 2N. Inheritance is generally autosomal dominant (Table 1) . Type 3 (which accounts for 1 to 5 percent of cases) is transmitted as an autosomal recessive trait in homozygous or compound heterozygous persons and is characterized by very low or undetectable levels of von Willebrand factor in plasma (less than 1 percent of normal plasma levels), with low but usually detectable levels of factor VIII (1 to 10 percent of normal plasma levels). 16 It is in these rare cases of type 3 disease (1 in 1 million people) that symptoms are more frequent and severe, similar to those in cases of moderately severe hemophilia A. 13 At the moment, no genotypic classification of von Willebrand's disease is available. More than 250 mutations of all types (including large and small deletions, out-of-frame insertions, splicing abnormalities, and nonsense and missense mutations) have been identified. More information on the genetic aspects of von Willebrand's disease can be found at www.sheffield.ac.uk/vwf and in a recent review article. 17 Normal screening tests of coagulation, such as measuring the activated partial-thromboplastin time and prothrombin time, do not rule out von Willebrand's disease. Before the 1970s, the disease could be diagnosed only on the basis of low plasma levels of factor VIII and a prolonged bleeding time (the bleeding time is normal in hemophilia A). 18 More laboratory diagnosis , and collagen receptors GpVI and a 2 b 1 with von Willebrand factor and collagen fibrils localized in the subendothelial extracellular matrix. When the vessel wall is intact and blood flow is normal, plasma von Willebrand factor that is present in a coiled structure and platelets coexist in circulating blood with minimal interactions. In the damaged vessel wall (Panel B), collagen and von Willebrand factor of the subendothelial matrix become exposed to flowing blood and shear forces. Plasma von Willebrand factor efficiently binds to exposed collagen and uncoils its structure, supporting the adhesion of circulating platelets in synergy with collagen. Bound von Willebrand factor interacts, at first, only with the platelet receptor GpIb a and platelet tethering occurs. This interaction has a fast dissociation rate, and platelets tethered to the vessel wall still move in the direction of flow (rolling). In this interaction, collagen receptors GpVI and a 2 b 1 bind to collagen and promote platelet adhesion and activation in synergy with the von Willebrand factor-GpIb a interactions. Once platelets are activated (represented by irregular margins), a conformational change of a IIb b 3 enhances its affinity for the ligand von Willebrand factor (receptors are shown as yellow crosses). This event, together with the rolling of platelets due to the von Willebrand factor-GpIb a interaction, allows a IIb b 3 to bind platelets to the vessel wall (Panel C); a IIb b 3 is also responsible for platelet-to-platelet interactions that eventually lead to platelet-plug formation mediated by von Willebrand factor and, at slow flow conditions, by fibrinogen (not shown).
specific assays for von Willebrand factor were subsequently developed, such as those measuring the immunoreactive protein (von Willebrand factor antigen) 19 and its binding to the platelet membrane glycoprotein Ib a , mediated by the antibiotic ristocetin (ristocetin cofactor activity), 20, 21 and to collagen fibrils. 22, 23 Other diagnostic methods measure the capacity of von Willebrand factor to bind (and thereby stabilize) factor VIII 24 or evaluate the multimeric pattern of the protein. 25, 26 Owing to the limited sensitivity, specificity, and reproducibility of these tests, none of them alone suffices to make a diagnosis. In general, hemostasis laboratories diagnose von Willebrand's disease with four relatively simple tests that measure bleeding time and levels of factor VIII, von Willebrand factor antigen, and ristocetin cofactor activity. Multimeric analysis and the factor VIII binding assay require more specialized expertise but are necessary because distinguishing among the subtypes of the disease has therapeutic implications, as described below. The limitations of the available assays of von Willebrand factor function should be kept in mind when results are interpreted in the clinical context. For instance, the bleeding time, still largely used for diagnostic purposes because it provides information about platelet-plug formation in vivo, is neither specific for nor sensitive to mild deficiencies of von Willebrand factor. Hence, a normal bleeding time does not exclude the possibility of some types of von Willebrand's disease. In vitro alternatives to this test, such as a test performed with a platelet-function analyzer, have variable sensitivity and specificity. 27, 28 Ristocetin cofactor activity and collagen binding activity are artificial surrogates for the platelet-dependent functions of von Willebrand factor and the adhesion of the protein to subendothelial collagen (Fig. 1) . The preoperative measurement of von Willebrand factor antigen is of little help in predicting bleeding in patients with type 1 von Willebrand's disease. 29 In von Willebrand's disease, as in hemophilia, the mainstay of treatment is the replacement of the deficient protein at the time of spontaneous bleeding or before invasive procedures are performed. Regular prophylaxis is not used as frequently as it is in general principles of treatment The new england journal of medicine patients with hemophilia A and B, because the bleeding tendency is usually less severe. However, prophylaxis should be contemplated in patients with type 3 disease who have had recurrent hemorrhages in the joints or in the gastrointestinal tract. In hemophilia A and B, the choice of treatment and dosage is based on the close relation among the factor VIII or factor IX content in replacement materials, the corresponding postinfusion plasma levels, and control of bleeding. 30 This equation is only partially relevant in von Willebrand's disease, because it is still uncertain which laboratory measurement best correlates with the severity of bleeding and its control by treatment. Plasma factor VIII is the most important determinant of surgical and softtissue bleeding, 31,32 but it is not clear which measurement is the most important determinant of mucosal tract bleeding. [33] [34] [35] Little information exists about the levels of ristocetin cofactor activity or collagen binding activity that are critical for the control of mucosal tract or surgical bleeding.
The mainstays of therapy are desmopressin, which induces secretion of autologous factor VIII and von Willebrand factor into plasma, and plasma concentrates, which supply allogeneic forms of these moieties. Fibrinolysis inhibitors, platelet concentrates, and oral estrogen-progestogen preparations are administered as adjuvant treatments.
is a synthetic derivative of antidiuretic hormone that acts through type 2 vasopressin receptors and is nearly devoid of activity through type 1 receptors. 36 In normal persons and in patients with mild hemophilia and von Willebrand's disease, desmopressin transiently increases both factor VIII and von Willebrand factor levels. 37 The advantages of using desmopressin as a therapeutic agent are its relatively low cost and unlimited availability and the fact that plasma concentrates can be avoided. The most likely mechanism by which desmopressin increases von Willebrand factor is through cyclic adenosine monophosphate signaling to mediate secretion from Weibel-Palade bodies in endothelial cells into plasma. 38 The site of storage and secretion of factor VIII is unknown.
dosage and routes of administration
Desmopressin, which is administered to children and adults at a dose of 0.3 µg per kilogram of body weight by continuous intravenous infusion for 30 minutes, increases plasma factor VIII and von Willebrand factor levels, on average, by three to five times the baseline levels within 30 to 60 minautologous replacement therapy * This mode of transmission is sometimes not evident because of reduced penetrance and varied expressivity. † Rare cases are characterized by autosomal recessive transmission. Because the response to desmopressin in each patient is generally consistent, 41 a test dose given at the time of diagnosis or before elective treatment is the best way to establish the individual pattern of response and to predict clinical efficacy. The test dose should be given at the doses discussed above, with the route of administration that will be adopted for treatment of bleeding. Factor VIII and ristocetin cofactor activity or collagen binding activity should be measured at least twice after the infusion -at one hour, to obtain information about the patient's peak level, and at four hours, to obtain information about the clearance rate. In practice, patients with any phenotype and plasma levels of factor VIII and von Willebrand factor in the range of 10 to 20 percent of the normal levels or higher before the administration of desmopressin are more likely than those with lower levels to have postinfusion levels that are sufficient to prevent or control bleeding. For instance, plasma levels of factor VIII and von Willebrand factor that are 10 percent of the normal levels are likely to increase to 30 to 50 percent of the normal levels after treatment; those increases may be sufficient for dental extraction, but not for major surgery. On the other hand, plasma factor levels that are 20 percent of the normal levels or more may increase to 60 to 100 percent after the administration of desmopressin, and these levels should be high enough for any surgical procedure. Since the increase in factor levels in plasma lasts for 8 to 10 hours after treatment, 39 desmopressin should be administered every 12 to 24 hours, if necessary. However, tachyphylaxis develops in some patients. 40 In general, treatment with desmopressin can be usefully repeated two to four times, but it is preferable to monitor the factor VIII response and tailor repeated treatments on the basis of the results. Fresh-frozen plasma contains both factor VIII and von Willebrand factor, but the large amounts that are needed to attain hemostatic concentrations (i.e., 20 to 25 ml per kilogram) may cause volume overload. Eight to 12 bags of cryoprecipitate, which contains both factors at higher concentrations than are found in plasma, normalize plasma factor levels and stop or prevent bleeding. 54 However, methods for virus inactivation are not routinely applicable to this plasma fraction. Hence, virus-inactivated plasma concentrates that contain both factor VIII and von Willebrand factor are considered to be safer and are preferable for patients who are not candidates for desmopressin treatment.
replacement products
Humate-P, one of the two commercial concentrates of antihemophilic factor that have been evaluated extensively in clinical studies, contains larger amounts of von Willebrand factor than it does factor VIII (by a factor of approximately two to three). [55] [56] [57] [58] The concentrate is pasteurized to inactivate blood-borne viruses. The other concentrate, Alphanate, contains similar relative amounts of factor VIII and ristocetin cofactor activity of von Willebrand factor 59 ; solvents and detergents, as well as heating at a high temperature, are used for virus inactivation. A few studies indicate that other commercial concentrates that contain both factors are also clinically efficacious, but the available data are limited and retrospective. [60] [61] [62] [63] Products containing highly purified factor VIII that are obtained by recombinant DNA techniques or from plasma should not be used because they lack von Willebrand factor, and the infused factor VIII therefore has a very short half-life. 64 A plasma concentrate that contains highly purified von Willebrand factor with very little factor VIII (Wilfactin) has been clinically evaluated in type 3 and other types of von Willebrand's disease. 65, 66 The rationale for its use is that patients with von Willebrand's disease have an intact endogenous production of factor VIII, provided the deficiency of its stabilizer is corrected by infusion of von Willebrand factor. The postinfusion levels of factor VIII rise slowly and peak between six and eight hours; therefore, in patients with baseline factor VIII levels that are 20 to 30 percent or less of normal levels, coadministration of a priming dose of factor VIII (for instance, a recombinant or monoclonal product) is necessary if hemostasis must be achieved promptly because of acute bleeding or emergency surgery. 66 Patients who undergo elective surgery should receive a concentrate infusion six to eight hours before the procedure in order to allow enough time for new synthesis of endogenous factor VIII. With the exception of plasma and cryoprecipitate, all plasma concentrates used for treatment so far lack the largest von Willebrand factor multimers, 67,68 but there is no evidence that their absence adversely affects the outcome of treatment. 59
dosage of concentrate
The average dosages of concentrates recommended for the control or prevention of different types of hemorrhages are shown in Table 2 . Since only a few prospective studies have gauged the effectiveness of the dosages, 57-59 the level of evidence supporting these recommendations is relatively low. Dosages in Table 2 are expressed in international units per kilogram of body weight for factor VIII coagulant activity, because most concentrates are labeled solely in terms of this moiety. The dosages are indicated for patients with severe deficiencies of both factor VIII and von Willebrand factor (levels that are approximately 10 percent or less of normal levels) and must be proportionally reduced in patients with less severe deficiencies in order to attain the same target levels of the factors. It is now frequently required that concentrates licensed for treatment of von Willebrand's disease be labeled with the potency of both ristocetin cofactor and factor VIII. 69 The recommended dosages of ristocetin cofactor are similar to those of factor VIII, 57-59 because the in vivo recovery of the two moieties is similar (i.e., approximately a 2 percent increase in plasma for each international unit per kilogram administered).
laboratory monitoring
When a patient undergoes surgery or receives repeated therapeutic doses of concentrates, factor VIII activity should be assayed every 12 hours on the day a dose is administered and every 24 hours thereafter. This is necessary not only because factor VIII is the main predictor of surgical hemostasis 31, 32, 35 but also to avoid reaching supranormal levels (i.e., 200 percent or more), which may increase the risk of venous thromboembolism (Fig. 3) . 70, 71 Treatallogeneic replacement therapy ment may also be monitored with ristocetin cofactor as a measure of von Willebrand factor activity. 69 The peak and trough plasma levels of ristocetin cofactor that are needed to achieve and maintain surgical hemostasis are similar to those of factor VIII. [57] [58] [59] However, monitoring ristocetin cofactor alone may be inappropriate during prolonged treatment, because plasma levels of this moiety fall rapidly, with a half-life of 8 to 10 hours, 55, 59 while factor VIII continues to rise to unnecessarily high levels as a result of endogenous factor VIII production (with a half-life of 24 to 26 hours, instead of 10 to 14 hours as in hemophilia A [ Fig. 3] ). Measuring the bleeding time is not necessary in the postoperative period. This test is often not normalized or even shortened in patients who are treated with cryoprecipitate 72 or concentrates. 68 Despite this fact, hemorrhage that is associated with surgical procedures and soft-tissue bleeding can be controlled successfully 31,32,55-59 if factor VIII levels are maintained at recommended levels ( Table 2) . When hemorrhage is not controlled despite adequate factor VIII levels, platelet concentrates given together with plasma products, at doses of 4¬10 11 to 5¬10 11 platelets, often control bleeding. [73] [74] [75] [76] Transfused normal platelets are thought to be hemostatically effective because they transport and localize von Willebrand factor from the rapidly flowing blood into the sites of vascular injury. 73, 75 Table 3 summarizes the options that are currently available for replacement therapy for the various phenotypes of von Willebrand's disease.
The manifestations of bleeding that are most frequently seen in von Willebrand's disease -such as epistaxis and menorrhagia -are sustained, in part, by the rich fibrinolytic activity of mucosal tracts. Local fibrinolytic activity in the buccal mucosa and gums also compromises hemostasis during dental extractions. These findings are the basis for the therapeutic use of antifibrinolytic amino acids in von Willebrand's disease, as well as in other inherited bleeding disorders. 77 Aminocaproic acid (at a dose of 50 to 60 mg per kilogram every 4 to 6 hours) or tranexamic acid (at a dose of 10 to 15 mg per kilogram every 8 to 12 hours) can be administered orally, intravenously, or topically. 77 Antifibrinolytic amino acids may be sufficient in the management of the less severe forms of mucosal bleeding. More often these agents are prescribed as adjuncts to replacement therapy with desmopressin and plasma concentrates during both minor and major surgery. Antifibrinolytic amino acids are associated with rare adverse effects such as nausea and diarrhea. They are contraindicated in patients with gross hematuria because clots that do not lyse may cause ureteral obstruction.
antifibrinolytic amino acids The new england journal of medicine Von Willebrand's disease does not impair fertility, and miscarriages do not occur with increased frequency. 13, 14 However, the disease has a negative effect on women's health and quality of life mainly because of menorrhagia and excessive bleeding at parturition.
menorrhagia
Among 271 women with no pelvic disease who had objectively documented excessive blood loss at menstruation, 7 to 13 percent had low von Willebrand factor levels. 78 Conversely, menorrhagia is a frequent symptom in women with von Willebrand's disease. 79, 80 For instance, in one study, 69 of 130 women with type 3 disease who were of childbearing age 13 had menstrual blood losses that were sufficient to cause iron-deficiency anemia. In women with type 3 disease, oral estrogen-progestogen preparations have a success rate as high as 88 percent in reducing blood loss, 14 probably because these drugs render the endometrium less susceptible to bleeding. Intranasal or subcutaneous administration of desmopressin, 81,82 antifibrinolytic amino acids, or both has also been proposed, but there is insufficient evidence of their efficacy, safety, and acceptability. Unlike type 1 vasopressin agonists, desmopressin has little or no oxytocic activity, so it can be used in pregnant women (those who are carriers of hemophilia A or who have type 1 von Willebrand's disease) before surgery or invasive diagnostic procedures, such as chorionic villus sampling and amniocentesis, are performed.
management of delivery
During and after delivery, measures aimed at rapid and complete contraction of the uterus are of utmost importance to prevent excessive bleeding. In women with type 1 disease, factor VIII and von Willebrand factor levels tend to rise spontaneously throughout pregnancy, 83 and often reach normal levels at term. Since factor VIII levels are the best predictor of bleeding during and after delivery, 84-87 they should be measured at term and for two weeks thereafter, when the factor VIII levels fall rapidly and bleeding may occur. The risk of bleeding after vaginal or cesarean delivery is minimal when plasma factor VIII levels are at least 30 to 40 percent of normal levels, but the risk may become clinically significant when they are lower. [84] [85] [86] [87] In these instances, it is necessary to administer desmopressin or concentrates at the time of delivery and for three to four days thereafter. Monitoring of the plasma factor VIII levels is of little use during pregnancy or delivery in women with type 3 disease, because the levels remain low. Daily doses of concentrates during and after delivery are needed to prevent bleeding (Table 2) . 13, 14 Alloantibodies that inactivate von Willebrand factor and form circulating immune complexes 88 develop in 10 to 15 percent of patients with type 3 disease who have received multiple transfusions, particularly in carriers of large gene deletions. 89 Concentrates that contain von Willebrand factor are contraindicated after this complication has occurred since they elicit life-threatening anaphylactic reactions be- Ristocetin cofactor activity and factor VIII coagulant activity are shown in a patient who had undergone elective hip replacement and who was treated repeatedly with a plasma concentrate containing factor VIII and von Willebrand factor, with doses determined on the basis of ristocetin cofactor activity. The black arrows show the times of administration of the concentrate. In an attempt to keep ristocetin cofactor activity close to 100 percent in the early postoperative period (up to day 9), 50 IU per kilogram of body weight of this moiety was given at approximately daily intervals. The target levels of ristocetin cofactor activity were achieved, but factor VIII levels increased progressively to more than 400 percent of the normal value. On postoperative day 12, a nonfatal pulmonary embolism developed in the patient, who had received no antithrombotic prophylaxis. Low-molecular-weight heparin should be given prophylactically to patients who are undergoing surgery, with the use of the same doses and schedules that are recommended for patients without von Willebrand's disease who are undergoing similar procedures. cause of complement activation by immune complexes. 90, 91 There is limited but favorable experience with the use of recombinant factor VIII, which is completely devoid of von Willebrand factor and therefore does not cause the formation of immune complexes. 91, 92 Since the plasma half-life of factor VIII in the absence of its carrier is very short (one to two hours) in patients with alloantibodies, 35, 91 recombinant factor VIII must be administered by continuous intravenous infusion at very large doses, with the goal of maintaining plasma factor VIII at hemostatic levels until bleeding stops (Table 2) . 91, 92 There is favorable experience with the use of recombinant activated factor VII. Studies have shown that bolus doses of 90 µg per kilogram given every two hours or 20 µg per kilogram given every hour by continuous intravenous infusion provide surgical hemostasis. 93, 94 An acquired syndrome that resembles von Willebrand's disease in its clinical manifestations and laboratory patterns occurs in rare instances in association with clinical conditions such as lymphoproliferative and autoimmune diseases, essential thrombocythemia, cancer, and valvular heart disease (particularly aortic stenosis). 95 The prevailing mechanisms are accelerated clearance of von Willebrand factor from plasma because of its absorption on the surface of abnormal cells, formation of complexes with other plasma proteins, heightened in vivo proteolysis, and inactivating autoantibodies. 95 The most successful form of treatment is the removal of the underlying cause of the condition, which usually leads to a resolution of the syndrome -for example, valve replacement in aortic stenosis. 96, 97 Other options for therapy are the administration of desmopressin, factor concentrates, and intravenous immune globulin. 98 The choice among these options is often determined by the increase in plasma factor levels after the administration of test doses.
A recombinant preparation of von Willebrand factor with an intact multimeric structure and adequate post-translational modifications corrects the plasma defects in dogs with von Willebrand's disease. 99 brand factor levels, which is distinct from the rapid and short-lasting rise observed after the administration of desmopressin. 103 If the cytokine appears to be effective and safe in clinical trials, it may provide a new form of treatment that would complement desmopressin, with the choice of the latter when a short-term hemostatic effect is needed and of interleukin-11 when a sustained effect is needed. Although gene therapy is being evaluated for hemophilia A and B in phase I clinical studies, 30 this approach is less attractive as a treatment for von Willebrand's disease. Although von Willebrand's disease occurs as frequently as hemophilia, it is usually not as severe, and adequate therapeutic options are available. In addition, the huge size of the complementary DNA makes it difficult to insert it into currently available viral vectors, and massive overexpression of the normal allele is required in the more frequent dominant forms of the disease (type 1, type 2A, and type 2B).
In the past 15 to 20 years, there have been major advances in our understanding of the pathophysiology, molecular basis, and management of von Willebrand's disease. The main options that are available for treatment (desmopressin and plasma concentrates) are effective in controlling bleeding in most patients with the disease. Even though virus-inactivated products appear to have an acceptable level of safety, it is hoped that the von Willebrand factor that is produced by recombinant DNA techniques will soon undergo clinical trials and become available for replacement therapy.
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